Thursday, March 26, 2020 7:20:31 PM
TEVA Sup/Res Distribution
Current resistance is shown as 8.16 -- what the middle orange arrow is pointing at. The distribution (on the right) is based on closing prices (as can be seen by the message at the top of the chart). Using opening prices would shift SR levels and give things a little different look. Using both together would smudge up the distribution, and just add confusion.
As current price attempts to move higher, it will tend to stay a little lower than overhead resistance, which is currently focused at $8.16 (as computed over 13-months of data). TEVA has risen significantly this week. For those reasons I choose to do nothing with my current $8 CC trade on TEVA. I'll ride it one more day and either my shares get assigned at $8 or they don't. Either way, I'll be owning TEVA shares again next week -- then I'll let them drift for a day or two and decide when and if and where to write more CCs against the shares. Wash, rinse, repeat every week -- gotta love those dividends the CCs bring in!
One more thing: I tend to look at this last seven trading days as a short pennant pattern off the bottom. A breakout higher could carry the stock $2 higher pretty fast. Wouldn't that be great! This is my only trade; and I'm 100% in, two accounts.
Oh, another one more thing. TEVA is a pharma company -- duh. It seems that group of companies should benefit the most from this virus thingy as all the drugs that solve these problems that the whole world is now sucked into originate from pharma companies. Apparently I'm wrong because I haven't seen pharma companies being treated any better during this decline. Will it finally become evident as earnings come out?
Current resistance is shown as 8.16 -- what the middle orange arrow is pointing at. The distribution (on the right) is based on closing prices (as can be seen by the message at the top of the chart). Using opening prices would shift SR levels and give things a little different look. Using both together would smudge up the distribution, and just add confusion.
As current price attempts to move higher, it will tend to stay a little lower than overhead resistance, which is currently focused at $8.16 (as computed over 13-months of data). TEVA has risen significantly this week. For those reasons I choose to do nothing with my current $8 CC trade on TEVA. I'll ride it one more day and either my shares get assigned at $8 or they don't. Either way, I'll be owning TEVA shares again next week -- then I'll let them drift for a day or two and decide when and if and where to write more CCs against the shares. Wash, rinse, repeat every week -- gotta love those dividends the CCs bring in!
One more thing: I tend to look at this last seven trading days as a short pennant pattern off the bottom. A breakout higher could carry the stock $2 higher pretty fast. Wouldn't that be great! This is my only trade; and I'm 100% in, two accounts.
Oh, another one more thing. TEVA is a pharma company -- duh. It seems that group of companies should benefit the most from this virus thingy as all the drugs that solve these problems that the whole world is now sucked into originate from pharma companies. Apparently I'm wrong because I haven't seen pharma companies being treated any better during this decline. Will it finally become evident as earnings come out?
Recent TEVA News
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 03/31/2026 08:43:03 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/31/2026 08:41:07 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/31/2026 08:38:29 PM
- Teva Gains Biosimilar Momentum with U.S. FDA Approval of PONLIMSI™ (denosumab-adet) and Dual Filing Acceptance for Biosimilar Candidate to Xolair® (omalizumab) • GlobeNewswire Inc. • 03/30/2026 12:00:00 PM
- Teva Releases Q1 2026 Aide Memoire • GlobeNewswire Inc. • 03/19/2026 08:30:00 PM
- Teva to Host Conference Call to Discuss First Quarter 2026 Financial Results at 8 a.m. ET on April 29, 2026 • GlobeNewswire Inc. • 03/19/2026 08:30:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/04/2026 10:36:38 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/04/2026 10:28:47 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/04/2026 10:22:25 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/03/2026 10:46:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/03/2026 10:34:28 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/03/2026 10:25:46 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/03/2026 10:13:29 PM
- Teva and Blackstone Life Sciences Announce $400 Million Strategic Growth Capital Agreement to Advance duvakitug • GlobeNewswire Inc. • 03/03/2026 10:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/02/2026 09:01:38 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/26/2026 09:11:04 PM
- Teva to Present at the Upcoming Investor Conferences in March • GlobeNewswire Inc. • 02/24/2026 09:30:00 PM
- Medincell: U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults • Business Wire • 02/20/2026 08:37:00 PM
- Medincell : La FDA américaine accepte le dossier de demande de mise sur le marché déposé par Teva pour l’Olanzapine LAI • Business Wire • 02/20/2026 08:37:00 PM
- U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults • GlobeNewswire Inc. • 02/20/2026 07:43:11 PM
- Teva and Sanofi’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease • GlobeNewswire Inc. • 02/17/2026 11:00:00 AM
- Teva Canada Announces Approval of Expanded Indication of [Pr]AJOVY® (fremanezumab solution for subcutaneous injection), the First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine • PR Newswire (Canada) • 02/04/2026 01:05:00 PM
- Teva Canada annonce l'approbation de l'indication élargie de [Pr]AJOVY[MD] (frémanézumab, solution pour injection sous cutanée), le premier traitement préventif anti-CGRP indiqué pour la migraine épisodique pédiatrique • PR Newswire (Canada) • 02/04/2026 01:05:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/03/2026 01:58:40 PM
- Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential • GlobeNewswire Inc. • 01/28/2026 12:00:00 PM
